Premium
DAS 181 treatment of hematopoietic stem cell transplant patients with parainfluenza virus lung disease requiring mechanical ventilation
Author(s) -
Chalkias S.,
Mackenzie M.R.,
Gay C.,
Dooley C.,
Marty F.M.,
Moss R.B.,
Li T.,
Routh R.L.,
Walsh S.R.,
Tan C.S.
Publication year - 2014
Publication title -
transplant infectious disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.69
H-Index - 67
eISSN - 1399-3062
pISSN - 1398-2273
DOI - 10.1111/tid.12177
Subject(s) - medicine , hematopoietic stem cell transplantation , hematopoietic stem cell , lung , disease , mechanical ventilation , virus , haematopoiesis , stem cell , immunology , biology , genetics
Parainfluenza infection is a cause of significant morbidity and mortality in allogeneic hematopoietic stem cell transplant ( HSCT ) patients. DAS 181 is a novel antiviral agent with activity against influenza and parainfluenza. We report the first 2 cases, to our knowledge, of successful DAS 181 use in ventilated HSCT patients with severe parainfluenza lung disease.